WO2004059278A3 - Methods of screening for anti-inflammatory drugs and use thereof - Google Patents

Methods of screening for anti-inflammatory drugs and use thereof Download PDF

Info

Publication number
WO2004059278A3
WO2004059278A3 PCT/IL2003/001116 IL0301116W WO2004059278A3 WO 2004059278 A3 WO2004059278 A3 WO 2004059278A3 IL 0301116 W IL0301116 W IL 0301116W WO 2004059278 A3 WO2004059278 A3 WO 2004059278A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
screening
inflammatory drugs
selectin
small organic
Prior art date
Application number
PCT/IL2003/001116
Other languages
French (fr)
Other versions
WO2004059278A8 (en
WO2004059278A2 (en
Inventor
Paul Gregor
Nicholas Harris
Juraj Koppel
Original Assignee
Rimonyx Pharmaceuticals Ltd
Paul Gregor
Nicholas Harris
Juraj Koppel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rimonyx Pharmaceuticals Ltd, Paul Gregor, Nicholas Harris, Juraj Koppel filed Critical Rimonyx Pharmaceuticals Ltd
Priority to AU2003288698A priority Critical patent/AU2003288698A1/en
Priority to EP03780600A priority patent/EP1579214A4/en
Priority to US10/541,099 priority patent/US20060275214A1/en
Publication of WO2004059278A2 publication Critical patent/WO2004059278A2/en
Publication of WO2004059278A8 publication Critical patent/WO2004059278A8/en
Publication of WO2004059278A3 publication Critical patent/WO2004059278A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to methods for screening small organic compounds capable of inhibiting the interactions of glycosaminoglycans with effector cell adhesion molecules. Specifically, the present invention provides a method for screening of small organic compounds, the compounds inhibit the interaction of heparin with L-selectin or P-selectin. The compounds identified by the methods of the invention are useful for treating inflammatory disorders, autoimmune diseases and cancer.
PCT/IL2003/001116 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof WO2004059278A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003288698A AU2003288698A1 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof
EP03780600A EP1579214A4 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof
US10/541,099 US20060275214A1 (en) 2003-12-30 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL153762 2002-12-31
IL15376202A IL153762A0 (en) 2002-12-31 2002-12-31 Methods of screening for anti-inflammatory drugs and use thereof

Publications (3)

Publication Number Publication Date
WO2004059278A2 WO2004059278A2 (en) 2004-07-15
WO2004059278A8 WO2004059278A8 (en) 2004-09-02
WO2004059278A3 true WO2004059278A3 (en) 2005-03-03

Family

ID=29798407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/001116 WO2004059278A2 (en) 2002-12-31 2003-12-30 Methods of screening for anti-inflammatory drugs and use thereof

Country Status (4)

Country Link
EP (1) EP1579214A4 (en)
AU (1) AU2003288698A1 (en)
IL (1) IL153762A0 (en)
WO (1) WO2004059278A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045831A1 (en) * 1999-02-02 2000-08-10 Thomas Jefferson University Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2658092A (en) * 1991-09-12 1993-04-05 Novo Nordisk A/S A method of screening for inhibitors of heparin-binding protein
GB0119476D0 (en) * 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045831A1 (en) * 1999-02-02 2000-08-10 Thomas Jefferson University Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIAMOND ET AL.: "Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)", J. CELL. BIOL., vol. 130, no. 6, 1995, pages 1473 - 1482, XP002982966 *
HAUGEN ET AL.: "A cell-surface heparan sulfate proteoglycan mediates neural cell adhesion and spreading on a defined sequence from the C-terminal cell and heparin binding domain of fibronectin, FN-C/H II", J. NEUROSCI., vol. 12, no. 7, July 1992 (1992-07-01), pages 2597 - 2608, XP008041842 *
KOENIG ET AL.: "Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents", J. CLIN. INVEST., vol. 101, no. 4, 15 February 1998 (1998-02-15), pages 877 - 889, XP002982965 *
NELSON ET AL.: "Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation", BLOOD, vol. 82, no. 11, 1 December 1993 (1993-12-01), pages 3253 - 3258, XP000573628 *
PETER ET AL.: "Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18)", CIRCULATION, vol. 100, no. 14, 5 October 1999 (1999-10-05), pages 1533 - 1539, XP002982967 *

Also Published As

Publication number Publication date
EP1579214A4 (en) 2008-08-27
AU2003288698A1 (en) 2004-07-22
EP1579214A2 (en) 2005-09-28
AU2003288698A8 (en) 2004-07-22
WO2004059278A8 (en) 2004-09-02
WO2004059278A2 (en) 2004-07-15
IL153762A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
WO2007053844A3 (en) Compositions and methods for treating inflammatory disorders
WO2006076036A3 (en) Nanostructure assemblies, methods and devices thereof
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
WO2004098494A3 (en) Compounds, compositions, and methods
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
AU2006254902A8 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2002060867A3 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2003263753A1 (en) Molecular weight reduction of polysaccharides by electron beams
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
WO2007022121A3 (en) O-nitro compounds, pharmaceutical compositons thereof and uses thereof
WO2005025515A3 (en) Proteasome pathway inhibitors and related methods
WO2007021971A3 (en) Labeling compositions and methods of use for deterrent trackability
AU2003277574A1 (en) Depolymerization process
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
AU2003250753A1 (en) Method for producing organic compounds containing poly-dopo, and the use of the same
WO2005073127A3 (en) Method for dissolving carbon nanotubes and the use thereof
AU2006243194A8 (en) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
WO2007025089A3 (en) Triazole compounds and methods of making and using the same
AU2003261657A1 (en) Promoter for the production of hyaluronic acid containing ginsenoside compound k
NL1025044A1 (en) Bicyclic derivatives for the treatment of abnormal cell growth.
WO2004059278A8 (en) Methods of screening for anti-inflammatory drugs and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2004 UNDER (71) THE ADDRESS SHOULD READ "KIRYATWEIZMANN SCIENCE PARK"

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003780600

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003780600

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006275214

Country of ref document: US

Ref document number: 10541099

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10541099

Country of ref document: US